Search Results - Frederick L Locke

Refine Results
  1. 1

    A Cost-Effectiveness Analysis of Diffuse Large B-Cell Lymphoma Treatment Pathways in the United States by Anik R. Patel, Bradley Kievit, Ken Hasegawa, Markqayne Ray, Rishika Sharma, Sarahmaria Hofmann, Rob Blissett, Frederick L. Locke

    Published in MDM Policy & Practice (2025-06-01)
    Get full text
    Article


  2. 2

    Tumor gene expression signatures associated with outcome in large B−cell lymphoma treated with CD19-directed CAR T−cell therapy (axicabtagene ciloleucel) by Yuan Tian, Justin Budka, Frederick L. Locke, Jason R. Westin, Christina To, Gayatri Tiwari, Daqin Mao, Davide Bedognetti, Rhine R. Shen, Jorge Andrade, Simone Filosto

    Published in Frontiers in Oncology (2025-02-01)
    Get full text
    Article


  3. 3

    Transverse myelitis after anti‐CD19 directed CAR T cell therapy for relapsed large B cell lymphoma by Semira Sheikh, Sepideh Mokhtari, Jeffrey A. Silverman, Kayla Reid, Rawan Faramand, Marco L. Davila, Norman Franke, Frederick L. Locke, Michael D. Jain, Daniel Wong, John G. Kuruvilla

    Published in eJHaem (2022-02-01)
    Get full text
    Article


  4. 4

    4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells by Frederick L Locke, Yannick Bulliard, Bin Yu, Marco L Davila, Emiliano Roselli, Justin C Boucher, Gongbo Li, Hiroshi Kotani, Kristen Spitler, Kayla Reid, Estelle V Cervantes, Nhan Tu, Sae Bom Lee

    Published in Journal for ImmunoTherapy of Cancer (2021-10-01)
    Get full text
    Article


  5. 5

    Radiomic features of PET/CT imaging of large B cell lymphoma lesions predicts CAR T cell therapy efficacy by Yoganand Balagurunathan, Zhouping Wei, Jin Qi, Zachary Thompson, Erin Dean, Erin Dean, Hong Lu, Hong Lu, Saran Vardhanabhuti, Salvatore Corallo, Jung W. Choi, Jenny J. Kim, Mike Mattie, Michael Jain, Frederick L. Locke

    Published in Frontiers in Oncology (2024-11-01)
    Get full text
    Article


  6. 6

    Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary disease by Ziad Abuhelwa, Ziad Abuhelwa, Fnu Amisha, Fnu Amisha, Wenyi Fan, Gabriel De Avila, Gabriel De Avila, Doris K. Hansen, Doris K. Hansen, Ariel F. Grajales-Cruz, Ariel F. Grajales-Cruz, Brandon Blue, Brandon Blue, Omar Castaneda, Omar Castaneda, Hien Liu, Hien Liu, Ciara L. Freeman, Ciara L. Freeman, Taiga Nishihori, Taiga Nishihori, Frederick L. Locke, Frederick L. Locke, Kenneth H. Shain, Kenneth H. Shain, Rachid Baz, Rachid Baz, Melissa Alsina, Melissa Alsina

    Published in Frontiers in Oncology (2025-10-01)
    Get full text
    Article


  7. 7

    Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease by Joseph Pidala, Jongphil Kim, Melissa Alsina, Ernesto Ayala, Brian C. Betts, Hugo F. Fernandez, Teresa Field, Heather Jim, Mohamed A. Kharfan-Dabaja, Frederick L. Locke, Asmita Mishra, Taiga Nishihori, Leonel Ochoa-Bayona, Lia Perez, Marcie Riches, Claudio Anasetti

    Published in Haematologica (2015-07-01)
    Get full text
    Article


  8. 8

    Modulating the polyamine/hypusine axis controls generation of CD8+ tissue-resident memory T cells by Aya G. Elmarsafawi, Rebecca S. Hesterberg, Mario R. Fernandez, Chunying Yang, Lancia N.F. Darville, Min Liu, John M. Koomen, Otto Phanstiel IV, Reginald Atkins, John E. Mullinax, Shari A. Pilon-Thomas, Frederick L. Locke, Pearlie K. Epling-Burnette, John L. Cleveland

    Published in JCI Insight (2023-09-01)
    Get full text
    Article


  9. 9

    A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation by Joseph Pidala, Jongphil Kim, Heather Jim, Mohamed A. Kharfan-Dabaja, Taiga Nishihori, Hugo F. Fernandez, Marcie Tomblyn, Lia Perez, Janelle Perkins, Mian Xu, William E. Janssen, Anandaraman Veerapathran, Brian C. Betts, Frederick L. Locke, Ernesto Ayala, Teresa Field, Leonel Ochoa, Melissa Alsina, Claudio Anasetti

    Published in Haematologica (2012-12-01)
    Get full text
    Article


  10. 10

    The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma by Kai Rejeski, Doris K. Hansen, Radhika Bansal, Pierre Sesques, Sikander Ailawadhi, Jennifer M. Logue, Eva Bräunlein, David M. Cordas dos Santos, Ciara L. Freeman, Melissa Alsina, Sebastian Theurich, Yucai Wang, Angela M. Krackhardt, Frederick L. Locke, Emmanuel Bachy, Michael D. Jain, Yi Lin, Marion Subklewe

    Published in Journal of Hematology & Oncology (2023-07-01)
    Get full text
    Article


  11. 11

    Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry by Frederick L Locke, Grant Schofield, Marcelo Pasquini, Matthew J Frigault, Cameron J Turtle, Stephen Lim, Brian Hill, Samantha Jaglowski, Caron A Jacobson, Gunjan Shah, Daniel J Landsburg, Michael Heim, Stephen Ronan Foley, Ron Ram, Peter A Riedell, Leslie L Popplewell, Ranjan Tiwari, Marta Majdan, Aisha Masood

    Published in Journal for ImmunoTherapy of Cancer (2025-02-01)
    Get full text
    Article


  12. 12

    IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation by Brian C. Betts, Joseph Pidala, Jongphil Kim, Asmita Mishra, Taiga Nishihori, Lia Perez, Jose Leonel Ochoa-Bayona, Farhad Khimani, Kelly Walton, Ryan Bookout, Michael Nieder, Divis K. Khaira, Marco Davila, Melissa Alsina, Teresa Field, Ernesto Ayala, Frederick L. Locke, Marcie Riches, Mohamed Kharfan-Dabaja, Hugo Fernandez, Claudio Anasetti

    Published in Haematologica (2017-05-01)
    Get full text
    Article


  13. 13

    In vivo IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation by Joseph Pidala, Francisca Beato, Jongphil Kim, Brian Betts, Heather Jim, Elizabeth Sagatys, John E. Levine, James L.M. Ferrara, Umut Ozbek, Ernesto Ayala, Marco Davila, Hugo F. Fernandez, Teresa Field, Mohamed A. Kharfan-Dabaja, Divis Khaira, Farhad Khimani, Frederick L. Locke, Asmita Mishra, Michael Nieder, Taiga Nishihori, Lia Perez, Marcie Riches, Claudio Anasetti

    Published in Haematologica (2018-03-01)
    Get full text
    Article


  14. 14

    Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel by Frederick L. Locke, Tanya Siddiqi, Caron A. Jacobson, Sarah Nikiforow, Sairah Ahmed, David B. Miklos, Yi Lin, Matthew A. Lunning, Brian T. Hill, Armin Ghobadi, Zhen-Huan Hu, Michael T. Hemmer, Michael J. Zoratti, Suresh Vunnum, Jonathan Tsang, Clare Spooner, Harry Smith, Christine Fu, Anik Patel, Harry Miao, Shilpa A. Shahani, Debbie L. Mirjah, Hairong Xu, Marcelo C. Pasquini

    Published in Blood Advances (2025-06-01)
    Get full text
    Article


  15. 15

    Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma by Jennifer M. Logue, Elisa Zucchetti, Christina A. Bachmeier, Gabriel S. Krivenko, Victoria Larson, Daniel Ninh, Giovanni Grillo, Biwei Cao, Jongphil Kim, Julio C. Chavez, Aliyah Baluch, Farhad Khimani, Aleksandr Lazaryan, Taiga Nishihori, Hien D. Liu, Javier Pinilla-Ibarz, Bijal D. Shah, Rawan Faramand, Anna E. Coghill, Marco L. Davila, Bhagirathbhai R. Dholaria, Michael D. Jain, Frederick L. Locke

    Published in Haematologica (2020-04-01)
    Get full text
    Article


  16. 16

    636 BASECAMP-1: A master prescreening study to identify patients with high-risk or metastatic solid tumors with HLA loss of heterozygosity (LOH) in preparation for Tmod CAR T-cell... by Marcela Maus, Caron Jacobson, Frederick L Locke, Oliver Dorigo, David Maloney, Jennifer Specht, Saurabh Dahiya, Edward Garon, Diane M Simeone, John Welch, Kedar Kirtane, Marwan Fakih, Julian Molina, Ariane Lozac’hmeur, J Randolph Hecht, Jong Chul Park, Caleb Smith, Theodore Welling, M Pia Morelli, Patrick M Grierson, Tomislav Dragovich, William Y Go, Eric W Ng, Peter Vu, Jessica Tebbets, Gayanie Ong

    Published in Journal for ImmunoTherapy of Cancer (2023-11-01)
    Article


  17. 17

    Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma by Stefanie Palfi, Lauren C. Peres, Himara Koelmeyer, Melissa Alsina, Rachid C. Baz, Brandon J. Blue, Salvatore Corallo, Gabriel De Avila, Ciara Freeman, Rebecca Gonzalez, Ariel Grajales-Cruz, Kristy Harvey, Hien D. Liu, Taiga Nishihori, Guilherme H. Oliveira, Laura B. Oswald, Omar Castaneda Puglianini, Sruthi Selvakumar, Alexis Behne Sharma, Elicia Wang, Kenneth H. Shain, Michael Jain, Frederick L. Locke, Mohammed Alomar, Doris K. Hansen, Dae Hyun Lee

    Published in Blood Cancer Journal (2025-04-01)
    Get full text
    Article


  18. 18

    Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel by Saurabh Zanwar, Surbhi Sidana, Leyla Shune, Omar Castaneda Puglianini, Oren Pasvolsky, Rebecca Gonzalez, Danai Dima, Aimaz Afrough, Gurbakhash Kaur, James A. Davis, Megan Herr, Hamza Hashmi, Peter Forsberg, Douglas Sborov, Larry D. Anderson Jr, Joseph P. McGuirk, Charlotte Wagner, Alex Lieberman-Cribbin, Adriana Rossi, Ciara L. Freeman, Frederick L. Locke, Shambavi Richard, Jack Khouri, Yi Lin, Krina K. Patel, Shaji K. Kumar, Doris K. Hansen

    Published in Journal of Hematology & Oncology (2024-06-01)
    Get full text
    Article


  19. 19

    Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel by Satabdi Saha, Lubna Rehman, Abdur Rehman, Faezeh Darbaniyan, Donna M. Weber, Melody Becnel, Mahmoud Gaballa, Sheeba K. Thomas, Hans C. Lee, Chia-Chi Chang, Reetakshi Arora, Meghan Menges, Salvatore Corallo, Marco L. Davila, Frederick L. Locke, Mark R. Tanner, Sattva S. Neelapu, Elizabeth J. Shpall, Christopher R. Flowers, Robert Z. Orlowski, Robert R. Jenq, Michael D. Jain, Christine Peterson, Doris K. Hansen, Neeraj Y. Saini, Krina K. Patel

    Published in Blood Advances (2025-07-01)
    Get full text
    Article


  20. 20

    Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing by Xuefeng Wang, Paulo C Rodriguez, Frederick L Locke, Xiaoqing Yu, Marco L Davila, Salvatore Corallo, Bijal Shah, Kayla Reid, Michael D Jain, Sean J Yoder, Chaomei Zhang, Reginald Atkins, Meghan A Menges, Ling Cen, Jerald D Noble, Turab J Mohammad, Christina A Bachmeier, Samira Naderinezhad, Lanmin Zhang, Julieta Abraham Miranda, Julio C Chavez, Rebecca S Hesterberg, Luis Cuadrado Delgado, Constanza Savid-Frontera, John L Cleveland

    Published in Journal for ImmunoTherapy of Cancer (2025-07-01)
    Get full text
    Article


Search Tools: